Were excited to now offer Tirzepatide, a next-generation medical weight management treatment designed to support sustainable, long-term results
Commercial coverage is common for type 2 diabetes and less consistent for weight loss alone
is on the speakers bureaus of AbbVie, Alexion Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chiesi Farmaceutici SpA, GMP-Orphan SAS, Norgine, Novartis, Univar, Wilson Therapeutics and Vivet Therapeutics and has received grants (to the institution) from Alexion Pharmaceuticals, Bayer, Bristol-Myers Squibb, Eisai, GMP-Orphan SAS, Novartis, Univar and Wilson Therapeutics
1 In clinical trials, patients with higher antibody titers have been seen to have smaller reductions in A1C compared to those with low or negative titers
, ,